



## **Altering the balance between immune activation versus regulation in the skin to promote CD8+ T-cell activity within epithelial cancers**

**Bridge, Jennifer A.; Overgaard, Nana Haahr; Steptoe, Raymond; Frazer, Ian H.; Wells, James W.**

*Publication date:*  
2016

*Document Version*  
Peer reviewed version

[Link back to DTU Orbit](#)

*Citation (APA):*

Bridge, J. A., Overgaard, N. H., Steptoe, R., Frazer, I. H., & Wells, J. W. (2016). Altering the balance between immune activation versus regulation in the skin to promote CD8+ T-cell activity within epithelial cancers. Abstract from American Association for Cancer Research (AACR) Annual Meeting 2016, New Orleans, Louisiana, United States.

---

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

# Altering the balance between immune activation versus regulation in the skin to promote CD8<sup>+</sup> T-cell activity within epithelial cancers

Jennifer A. BRIDGE<sup>1</sup>, Nana H. OVERGAARD<sup>1</sup>, Raymond J. STEPTOE<sup>1</sup>, Ian H. FRAZER<sup>1</sup> and James W. WELLS<sup>1</sup>.

<sup>1</sup>The University of Queensland Diamantina Institute, The University of Queensland, Translational Research Institute, Brisbane, QLD 4102, AUSTRALIA, Email: [j.wells3@uq.edu.au](mailto:j.wells3@uq.edu.au)

The Human Papilloma Virus (HPV) 16 is a high-risk HPV known to be a causative agent in numerous cancers including cervical cancer. While prophylactic vaccines exist to combat the spread of HPV16, successful therapeutic vaccines to combat established HPV16-associated disease remain elusive. The expression, in a mouse model ("E7"), of the HPV16 E7 gene in keratinocytes under the control of the K14 promoter, leads to a local immune suppressive environment, as evidenced by the lack of graft rejection when E7 skin grafts are placed on WT recipient mice. Furthermore, well healed (>30 days) E7 skin grafts are not rejected when mice are immunised with E7 peptide in combination with Quil A- or CASAC-based adjuvants. This is despite a substantial increase in E7 peptide/H-2D<sup>b</sup> pentamer staining in the blood, and marked killing of E7-peptide expressing TC-1 cells when injected i.v., confirming that CD8 T-cells respond to vaccination and differentiate into CTL capable of killing E7-expressing target cells. We hypothesised that the removal of regulatory T-cells (T-reg) might lead to E7 graft rejection in immunised mice. The co-administration of an anti-CD4-depleting antibody at the time of immunisation led to rejection of ~50% of grafts. To confirm a role for T-reg, E7-grafted T-reg-deficient Rag1<sup>-/-</sup> mice received purified donor CD8 T-cells from E7-vaccinated WT mice. FACS staining of Rag1<sup>-/-</sup> lymph nodes 30 days post CD8<sup>+</sup> T-cell transfer confirmed the absence of classical CD4<sup>+</sup>FoxP3<sup>+</sup> Treg, however the E7 grafts did not reject. As in the WT mice however, rejection could be induced through the co-administration of an anti-CD4 antibody. The data suggest that the removal of a CD4<sup>+</sup>, non T-reg cell, leads to CD8<sup>+</sup> T-cell activity in the skin as evidenced by E7 skin graft destruction.